Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + MK-0482 + carboplatin + paclitaxel
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
This combination therapy consists of pembrolizumab (a monoclonal antibody targeting PD-1), MK-0482 (a novel humanized IgG4 monoclonal antibody targeting immunoglobulin-like transcript 3, ILT3), carboplatin, and paclitaxel (both cytotoxic chemotherapeutic agents). Pembrolizumab acts as an immune checkpoint inhibitor, blocking PD-1 to enhance anti-tumor immune responses. MK-0482 is designed to inhibit ILT3, a receptor that suppresses immune activation in the tumor microenvironment, thereby potentially relieving immunosuppression and augmenting immune-mediated tumor killing. Carboplatin is a platinum agent that causes DNA crosslinking and cell death, and paclitaxel stabilizes microtubules, inhibiting cell division. This multi-agent regimen is being studied for its potential synergistic anti-tumor efficacy, including in previously untreated or advanced solid tumors such as metastatic pancreatic ductal adenocarcinoma (mPDAC)[2][1].
- Other names
- pembrolizumab + MK-0482 + carboplatin + paclitaxel
02
Targets
BCL-2 (BCL-2 family)TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)LILRB4DNA
Beyond the preview
Go deeper on pembrolizumab + MK-0482 + carboplatin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + MK-0482 + carboplatin + paclitaxel.